Back to search results

Understanding Immunotherapy Response in Non-Small Cell Lung Cancer

This study aims to understand why some people with Non-Small Cell Lung Cancer (NSCLC) respond well to immunotherapy treatments, while others don't. Researchers will collect blood, stool, and tissue samples from patients before and during their treatment. They will look for connections between specific biological features in these samples and how well patients respond to immunotherapy. The goal is to create a tool that can predict which patients might benefit most from these treatments. You may be able to join if you are at least 18 years old, have NSCLC, and meet certain health criteria (ECOG PS - 0/1-2). The study will measure how well patients respond to treatment at 3, 6, and 9 months.

Study design
This is an observational study with a planned enrollment of 350 participants. It is not a treatment study but rather focuses on collecting information.
What's involved
You would provide blood, stool, and tissue samples before and during your cancer treatment. Clinical information about your disease and treatment will also be collected.
Compensation
Not stated in the trial record.
Follow-up
Your overall response to treatment will be measured at 3, 6, and 9 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05736029

Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments, Using Multiomics

Recruiting
Not specifiedAges 18+Observational
OncoHost Ltd.
~350 participants
Updated 2023-02-21 on ClinicalTrials.gov
What's tested:blood, stool and tissue samples collection

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Overall response (OR)
Measured over month 3
+26 more outcomes measured

Conditions

Non Small Cell Lung Cancer
Healthy

Explore related trials

HealthyLung Non-Small Cell Carcinoma

Where it's being run

1 sites across 1 states
Texas1

Study leadership

  • Ronan J Kelly, MD MBA · PRINCIPAL_INVESTIGATOR · Chief of Oncology Baylor Scott & White Health System

Who to contact

Galit Yahalom, PhD
[email protected]
97248537557
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Provision of informed consent prior to any study-specific procedures.
Male or female aged at least 18 years.
ECOG PS - 0/1-2.

Exclusion

Any concurrent and/or other active malignancy that has required systemic treatment within 2 years of first dose of treatment.
Generalized impairment or mental incompetence that would render the patient unable to understand his/her participation in the study.

What this trial measures

  • Overall response (OR)month 3

    OR as defined by RECIST 1.1 or any other validated clinical scale for response

  • Overall response (OR)month 6

    OR as defined by RECIST 1.1 or any other validated clinical scale for response

  • Overall response (OR)month 9

    OR as defined by RECIST 1.1 or any other validated clinical scale for response

  • Overall response (OR)month 12

    OR as defined by RECIST 1.1 or any other validated clinical scale for response

  • Overall response (OR)month 15

    OR as defined by RECIST 1.1 or any other validated clinical scale for response

  • Overall response (OR)month 18

    OR as defined by RECIST 1.1 or any other validated clinical scale for response

  • Overall response (OR)month 21

    OR as defined by RECIST 1.1 or any other validated clinical scale for response

  • Overall response (OR)month 24

    OR as defined by RECIST 1.1 or any other validated clinical scale for response

  • Plasma proteomic profileBaseline, pre treatment

    Plasma proteins measurments

  • Plasma proteomic profile2(+/-1) weeks from first treatment

    Plasma proteins measurments

  • Plasma proteomic profile3 months

    Plasma proteins measurments

  • Plasma proteomic profile6 months

    Plasma proteins measurments

  • Plasma proteomic profile9 months

    Plasma proteins measurments

  • Plasma proteomic profile12 months

    Plasma proteins measurments

  • Plasma proteomic profile15 months

    Plasma proteins measurments

  • Plasma proteomic profile18 months

    Plasma proteins measurments

  • Plasma proteomic profile21 months

    Plasma proteins measurments

  • Plasma proteomic profile24 months

    Plasma proteins measurments

  • Epigenetic patternsBaseline, pre treatment

    Characterization of Cell free DNA

  • Epigenetic patterns2(+/-1) weeks from first treatment

    Characterization of Cell free DNA

  • Epigenetic patterns12 months

    Characterization of Cell free DNA

  • Epigenetic patterns24 months

    Characterization of Cell free DNA

  • ctDNA mutation analysisimmediately after surgery

    ctDNA mutation analysis

  • Microbiome profilingBaseline, pre treatment

    PBMC subpopulations exploration

  • Microbiome profiling2(+/-1) weeks from first treatment

    PBMC subpopulations exploration

  • Microbiome profiling12 months

    PBMC subpopulations exploration

  • Microbiome profiling24 months

    PBMC subpopulations exploration